Julien Dumoulin-Smith: Hi, good morning, team. Thank you guys very much for the time, appreciate it and congratulations to everyone on the various stewards here. Just maybe if I can kick it off here, just coming back to ’23 and expectations, you talked about DELCORA and obviously the timing is shifting there a little bit, you’ve got this ATM, that’s certainly fluid and you talked about some cost pressures in the quarter. Can you give us a little bit of an update? I know you reaffirmed five to seven and midpoint here for ’22 but how are you thinking about it over the longer-term? What are some of these shifts position you as you think about ’23? Anything that just flag, I guess, that you haven’t launched your formal ’23 process yet? But maybe early indications, how do you think about some of the offsets here, maybe some additional capital starting to offset the impact of the timing for DELCORA and the associated spend that you would have done at DELCORA as well?
Christopher Franklin: Yes. I think, we’re looking at our budgeting now and we’re obviously our 2023 budget will be approved by the Board in December. But as things look right now and I said it in my comments, despite the continued delay in DELCORA, we remain confident in our previously discussed guidance. And so, we’ll have an update for you all and another month or so here. But at this point we remain confident that, we can achieve our long-term guidance that we’ve communicated already. Dan, anything to add?
Daniel Schuller: No, I think you covered it, Chris.
Julien Dumoulin-Smith: Okay. Could you guys talk about some of the offsets maybe just as you think about? I know it’s in flux, so maybe just speak to – through some of them here in terms of the ability to raise that adjust CapEx? And over the timing of the dilution itself as you think about clearly some of that capital raise would have been in tandem with third quarter itself you would think?
Christopher Franklin: Yes. I think you’re thinking about it the right way. You know, as we think about our capital spend, we do have some flexibility and obviously whether and our ability to execute against the capital budget, gives us some flexibility there not a ton, but there are levers we can pull there. And yes, listen, then I think discussed pretty well our equity needs. I think we’ve covered that.
Daniel Schuller: Yes. And I would say just add too, as you think about offsets and achieving objectives, that we’re constantly working with our state teams to look at their controllable expenses and make sure that we’re rebidding things and we’re getting the best contract with the best price. And all of our state team management teams have – they all have incentives in place, that really rely on them achieving their cost metrics. So they are incentivized to help drive cost-down as well.
Julien Dumoulin-Smith: Got it. Excellent. And you roll forward your outlook with the next update too?
Christopher Franklin: Yes. Well – our plan is to share all of our guidance just after the first of the year. And at this point we would anticipate that looks like guidance we’ve provided in the past, meaning EPS guidance for 2023, EPS growth rate guidance, capital guidance, and then the other ESG related metrics.
Julien Dumoulin-Smith: All right. Excellent team. Best of luck. Speak to you then. Cheers.
Christopher Franklin: Thanks, Julien.
Operator: The next question comes from the line of Gregg Orrill from UBS. Please go ahead.
Daniel Schuller: Hi, Gregg.
